Do free radicals play causal role in atherosclerosis? Low density lipoprotein oxidation and vitamin E revisited

Journal of Clinical Biochemistry and Nutrition

Volumn 48, Issue 1, 2011, Pages 3-7

  Niki, Etsuo ^a,b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Atherosclerosis; Biomarker; Free radical; Lipid peroxidation; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ARACHIDONIC ACID; ARYLDIALKYLPHOSPHATASE 1; BETA CAROTENE; BIOLOGICAL MARKER; CYTOCHROME P450; FREE RADICAL; HIGH DENSITY LIPOPROTEIN; HYDROXYICOSATETRAENOIC ACID; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; MONOCLONAL ANTIBODY LDL RECEPTOR IGG; MYELOPEROXIDASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; POLYUNSATURATED FATTY ACID; RADIOPHARMACEUTICAL AGENT; SINGLET OXYGEN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CANCER PREVENTION; DRUG EFFECT; DRUG EFFICACY; HUMAN; IN VITRO STUDY; LIPID PEROXIDATION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; VITAMIN SUPPLEMENTATION;

ANIMALIA;

EID: 78650719494     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.11-007FR     Document Type: Review

References (33)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924. (Pubitemid 19101597)
2. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 2009; 50 Suppl: S376-S381.
3. Miller YI, Choi SH, Fang L, Tsimikas S. Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. Subcell Biochem 2010; 51: 229-251.
4. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010; 23: 447-454.
5. Berliner JA, Territo MC, Sevanian A, and et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85: 1260-1266. (Pubitemid 20123772)
6. Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in atherosclerosis. J Lipid Res 2009; 50: 207-212.
7. Brown AJ, Jessup W. Oxysterols and atherosclerosis. Atherosclerosis 1999; 142: 1-28.
8. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res 2005; 96: 435-441. (Pubitemid 40354537)
9. Rossi L, Arciello M, Capo C, Rotilio G. Copper imbalance and oxidative stress in neurodegeneration. Ital J Biochem 2006; 55: 212-221.
10. Messner MC, Albert CJ, McHowat J, Ford DA. Identification of lysophosphatidylcholine-chlorohydrin in human atherosclerotic lesions. Lipids 2008; 43: 243-249.
11. Malle E, Marsche G, Arnhold J, Davies MJ. Modification of low-density lipoproteinby myelperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta 2006; 1761: 392-415. (Pubitemid 43776460)
12. Kühn H, Heydeck D, Hugou I, Gniwotta C. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest 1997; 99: 888-893.
13. Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med 2009; 47: 469-484.
14. Kitano S, Yoshida Y, Kawano K, Hibi N, Niki E. Oxidative status of human low density lipoprotein isolated by anion-exchange high-performance liquid chromatography: assessment by total hydroxyoctadecadienoic acid, 7-hydroxycholesterol, and 8-iso-prostaglandin F(2alpha). Anal Chim Acta 2007; 585: 86-93. (Pubitemid 46176792)
15. Van Lenten BJ, Navab M, Shis D, Fogelman AM, Lusis AJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001; 11: 155-161. (Pubitemid 33070340)
16. Shao B, Heinecke JW. HDL, lipid peroxidation, and athersoclerosis. J Lipid Res 2009; 50: 599-601.
17. Navab M, Reddy ST, Van Lenten BJ, Anantharamalah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; 50: S145-S149.
18. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89: 10316-10320.
19. Proudfoot JM, Barden AE, Loke WM, Croft KD, Puddey IB, Mori TA. HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res 2009; 50: 716-722.
20. Noguchi N, Niki E. Dynamics of vitamin E action against LDL oxidation. Free Radic Res 1998; 28: 561-572. (Pubitemid 28454249)
21. Cynshi O, Kawabe Y, Suzuki T, and et al. Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc Natl Acad Sci USA 1998; 95: 10123-10128.
22. Gey KF, Puska P. Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann NY Acad Sci 1989; 570: 268-282.
23. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-1456.
24. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444-1449. (Pubitemid 23143846)
25. Bonithon-Kopp C, Coudray C, Berr C, and et al. Combined effects of lipid peroxidation and antioxidant status on carotid atherosclerosis in a population aged 59-71 y: The EVA Study. Etude sur le Vieillisement Artériel. Am J Clin Nutr 1997; 65: 121-127.
26. Traber MG, Frei B, Beckman JS. Vitamin E revisited: do new data validate benefits for chronic disease prevention? Curr Opin Lipidol 2008; 19: 30-38.
27. Dotan Y, Pinchuk I, Lichtenberg D, Leshno M. Decision analysis supports the paradigm that indiscriminate supplementation of vitamin E does more harm than good. Arterioscler Thromb Vasc Biol 2009; 29: 1304-1309.
28. Cordero Z, Drogan D, Weikert C, Boeing H. Vitamin E and risk of cardiovascular diseases: a review of epidemiologic and clinical trial studies. Crit Rev Food Sci Nutr 2010; 50: 420-440.
29. Niki E. Assessment of antioxidant capacity in vitro and in vivo. Free Radic Biol Med 2010; 49: 503-515.
30. Rudd JH, Narula J, Strauss HW, and et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol 2010; 55: 2527-2535.
31. Ishino S, Mukai T, Kuge Y, and et al. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque. J Nucl Med 2008; 49: 1677-1685.
32. Riou LM, Broisat A, Dimastromatteo J, Pons G, Fagret D, Ghezzi C. Preclinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview. Curr Med Chem 2009; 16: 1499-1511.
33. Fang JC, Kinlay S, Beltrame J, and et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002; 359: 1108-1113.